Sotagliflozin Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for Sotagliflozin comprises 109 peer-reviewed publications across 15 journals, 14 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1, Sarcoidosis, and Heart Failure. Most recent publication: Modeling Cardiorenal Protection with Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: An Analysis of DEPICT-1 and DEPICT-2., Clin J Am Soc Nephrol, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Comparison of Exogenous Ketone Administration Versus Dietary Carbohydrate Restriction on Myocardial Glucose Suppression: A Crossover Clinical Trial.
    Selvaraj S, Margulies KB, Dugyala S, et al. · J Nucl Med · 2022
    PubMed: PMID 34675108 · NCT06510894 · Sarcoidosis
  2. Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure.
    Selvaraj S, Kelly DP, Margulies KB, et al. · Circulation · 2021
    PubMed: PMID 32479196 · NCT06510894 · Sarcoidosis
  3. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.
    Selvaraj S, Fu Z, Jones P, et al. · Circulation · 2023
    PubMed: PMID 35603596 · NCT06510894 · Sarcoidosis
  4. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
    Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. · J Am Coll Cardiol · 2020
    PubMed: PMID 30999996 · NCT06510894 · Sarcoidosis
  5. Utility of serum ketone levels for assessment of myocardial glucose suppression for 18F-fluorodeoxyglucose PET in patients referred for evaluation of endocarditis.
    Madamanchi C, Weinberg RL, Murthy VL, et al. · J Nucl Cardiol · 2023
    PubMed: PMID 36823484 · NCT06510894 · Sarcoidosis
  6. SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial.
    Lauritsen KM, Nielsen BRR, Tolbod LP, et al. · Diabetes · 2021
    PubMed: PMID 33334875 · NCT06510894 · Sarcoidosis
  7. The DAPA-DIET study: Metabolic response to Dapagliflozin combined with dietary carbohydrate restriction in patients with Type 2 Diabetes Mellitus and Obesity-A longitudinal cohort study.
    Hanson P, Randeva H, Cuthbertson DJ, et al. · Endocrinol Diabetes Metab · 2022
    PubMed: PMID 36266774 · NCT06510894 · Sarcoidosis
  8. The utility of beta-hydroxybutyrate in detecting myocardial glucose uptake suppression in patients undergoing inflammatory [18F]-FDG PET studies.
    Alfawara MS, Ahmed AI, Saad JM, et al. · Eur J Nucl Med Mol Imaging · 2023
    PubMed: PMID 36474124 · NCT06510894 · Sarcoidosis

Primary-outcome results across pivotal trials

Per-arm reported values from Phase 2/3 and Phase 3 trials with results posted to ClinicalTrials.gov.

TrialIndicationPrimary endpointArmValue
NCT02384941
inTandem1
Diabetes Mellitus, Type 1Change From Baseline in A1C at Week 24
Baseline to Week 24
Placebo-0.07 percentage of A1C (±0.036 Standard Error)
Sotagliflozin 200 mg-0.43 percentage of A1C (±0.036 Standard Error)
Sotagliflozin 400 mg-0.48 percentage of A1C (±0.036 Standard Error)
NCT02421510
inTandem2
Diabetes Mellitus, Type 1Change From Baseline in A1C at Week 24
Baseline to Week 24
Placebo-0.02 Percentage of A1C (±0.044 Standard Error)
Sotagliflozin 200 mg-0.39 Percentage of A1C (±0.044 Standard Error)
Sotagliflozin 400 mg-0.37 Percentage of A1C (±0.043 Standard Error)
NCT02531035
inTandem3
Diabetes Mellitus, Type 1Percentage of Participants With A1C <7.0% at Week 24 and No Episode of Severe Hypoglycemia and No Episode of Diabetic Ketoacidosis (DKA) After Randomization
Week 24
Placebo15.2 percentage of participants
Sotagliflozin 400 mg28.6 percentage of participants
NCT02926937Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26 (Sotagliflozin 400 mg Versus Placebo)
Baseline to Week 26
Placebo-0.34 percentage of HbA1c (±0.120 Standard Error)
Sotagliflozin 400 mg-1.03 percentage of HbA1c (±0.122 Standard Error)
NCT02926950Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26
Baseline and Week 26
Placebo + Metformin-0.29 percentage of HbA1c (±0.079 Standard Error)
Sotagliflozin 400 mg + Metformin-0.77 percentage of HbA1c (±0.077 Standard Error)
NCT03066830Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26
Baseline to Week 26
Placebo0.06 percentage HbA1c (±0.082 Standard Error)
Sotagliflozin 400 mg-0.70 percentage HbA1c (±0.068 Standard Error)
NCT03242018
SOTA-CKD4
Diabetes Mellitus, Type 2Change From Baseline in HbA1c at Week 26 Comparing Sotagliflozin 400 mg Versus Placebo
Baseline to Week 26
Placebo-0.11 percentage of HbA1c (±0.151 Standard Error)
Sotagliflozin 400 mg-0.40 percentage of HbA1c (±0.131 Standard Error)
NCT03242252
SOTA-CKD3
Diabetes Mellitus, Type 2Change From Baseline in HbA1c at Week 26
Baseline to Week 26
Placebo-0.22 percentage of HbA1c (±0.061 Standard Error)
Sotagliflozin 200 mg-0.32 percentage of HbA1c (±0.060 Standard Error)
Sotagliflozin 400 mg-0.46 percentage of HbA1c (±0.060 Standard Error)
NCT03285594
SOTA-INS
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c) at Week 18
Baseline and Week 18
Placebo-0.27 percentage of HbA1c (±0.073 Standard Error)
Sotagliflozin 200 mg-0.72 percentage of HbA1c (±0.073 Standard Error)
Sotagliflozin 400 mg-0.81 percentage of HbA1c (±0.056 Standard Error)
NCT03315143
SCORED
Diabetes Mellitus, Type 2Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF)
Up to 30 months
Placebo7.5 events per 100-person years
Sotagliflozin5.6 events per 100-person years
NCT03332771
SOTA-GLIM
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c at Week 52
Baseline, Week 52
Glimepiride-0.61 percentage of HbA1c (±0.093 Standard Error)
Placebo-0.40 percentage of HbA1c (±0.187 Standard Error)
Sotagliflozin 200 mg-0.49 percentage of HbA1c (±0.114 Standard Error)
Sotagliflozin 400 mg-0.65 percentage of HbA1c (±0.101 Standard Error)
NCT03351478
SOTA-EMPA
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c) % at Week 26
Baseline, Week 26
Empagliflozin 25 mg-0.8 percentage of HbA1c (±0.1 Standard Error)
Placebo-0.3 percentage of HbA1c (±0.1 Standard Error)
Sotagliflozin 400 mg-0.7 percentage of HbA1c (±0.1 Standard Error)
NCT03386344
SOTA-BONE
Diabetes Mellitus, Type 2Change From Baseline in Hemoglobin A1c (HbA1c) at Week 26
Baseline to Week 26
Placebo-0.22 percentage of HbA1c (±0.080 Standard Error)
Sotagliflozin 200 mg-0.66 percentage of HbA1c (±0.077 Standard Error)
Sotagliflozin 400 mg-0.67 percentage of HbA1c (±0.079 Standard Error)
NCT03521934Diabetes Mellitus, Type 2Number of Total Occurrences of Cardiovascular (CV) Death, Hospitalizations for Heart Failure (HHF) and Urgent Visits for Heart Failure (HF)
Up to 21.9 months
Placebo76.3 events per 100-person years
Sotagliflozin51 events per 100-person years

Publications by year

1979–2026: 109 publications.

1979
1
1993
1
2003
1
2004
2
2006
1
2008
1
2010
1
2011
1
2012
3
2013
2
2015
1
2016
1
2017
4
2018
6
2019
6
2020
11
2021
12
2022
14
2023
10
2024
20
2025
7
2026
3

Publications by indication

Diabetes Mellitus, Type 2 (47)

  • Residual Risk of Adverse Kidney and Cardiovascular Outcomes in Patients with CKD.
    Clin J Am Soc Nephrol · 2026 · PMID 39688924 · NCT07547878
  • Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial.
    Lancet Diabetes Endocrinol · 2025 · PMID 39961315 · NCT03315143
  • Relationship Between Hypoglycemia Awareness Status on Clarke/Gold Methods and Counterregulatory Response to Hypoglycemia.
    J Endocr Soc · 2025 · PMID 35935070 · NCT07547878
  • Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes.
    J Am Soc Nephrol · 2025 · PMID 40327845 · NCT07547878
  • Simultaneous or Rapid Initiation of Combination Therapy for Heart Failure With Preserved Ejection Fraction.
    JAMA Cardiol · 2025 · PMID 40042835 · NCT07547878

Diabetes Mellitus, Type 1 (42)

  • Modeling Cardiorenal Protection with Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: An Analysis of DEPICT-1 and DEPICT-2.
    Clin J Am Soc Nephrol · 2026 · PMID 39918875 · NCT06217302
  • Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 Diabetes.
    Diabetes Ther · 2026 · PMID 37740871 · NCT07325201
  • Experimental Designs for Multicomponent Interventions in Kidney and Cardiometabolic Diseases.
    J Am Soc Nephrol · 2024 · PMID 39078403 · NCT06082063
  • Harnessing the Synergy of SGLT2 Inhibitors and Continuous Ketone Monitoring (CKM) in Managing Heart Failure among Patients with Type 1 Diabetes.
    Healthcare (Basel) · 2024 · PMID 38610175 · NCT07325201
  • Expert Panel Recommendations for a Standardized Ambulatory Glucose Profile Report for Connected Insulin Pens.
    Diabetes Technol Ther · 2024 · PMID 38758213 · NCT07325201

Sarcoidosis (17)

  • Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.
    Circulation · 2023 · PMID 35603596 · NCT06510894
  • Utility of serum ketone levels for assessment of myocardial glucose suppression for 18F-fluorodeoxyglucose PET in patients referred for evaluation of endocarditis.
    J Nucl Cardiol · 2023 · PMID 36823484 · NCT06510894
  • The utility of beta-hydroxybutyrate in detecting myocardial glucose uptake suppression in patients undergoing inflammatory [18F]-FDG PET studies.
    Eur J Nucl Med Mol Imaging · 2023 · PMID 36474124 · NCT06510894
  • Comparison of Exogenous Ketone Administration Versus Dietary Carbohydrate Restriction on Myocardial Glucose Suppression: A Crossover Clinical Trial.
    J Nucl Med · 2022 · PMID 34675108 · NCT06510894
  • The DAPA-DIET study: Metabolic response to Dapagliflozin combined with dietary carbohydrate restriction in patients with Type 2 Diabetes Mellitus and Obesity-A longitudinal cohort study.
    Endocrinol Diabetes Metab · 2022 · PMID 36266774 · NCT06510894

Heart Failure (1)

  • Rationale and Design of the SOTA-THROMBOSIS Trial (ATRU-VI): Antithrombotic Activities of Sotagliflozin Compared With Empagliflozin.
    J Cardiovasc Pharmacol · 2025 · PMID 40748666 · NCT06618976

Diabetes Mellitus (1)

  • Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study.
    Diabetes Care · 2022 · PMID 35817022 · NCT03462069

Publications by journal

Trial-results highlights

For individuals with Type 1 Diabetes, clinical trials evaluated the effects of sotagliflozin on A1C levels. In NCT02384941 (inTandem1), the change from baseline in A1C at Week 24 was -0.43 percentage of A1C for the sotagliflozin 200 mg arm and -0.48 percentage of A1C for the sotagliflozin 400 mg arm, compared to -0.07 percentage of A1C for placebo. Similarly, in NCT02421510 (inTandem2), the change from baseline in A1C at Week 24 was -0.39 percentage of A1C for the sotagliflozin 200 mg arm and -0.37 percentage of A1C for the sotagliflozin 400 mg arm, versus -0.02 percentage of A1C for placebo. A third trial, NCT02531035 (inTandem3), reported that 28.6 percentage of participants in the sotagliflozin 400 mg arm achieved A1C <7.0% at Week 24 without severe hypoglycemia or diabetic ketoacidosis, compared to 15.2 percentage of participants in the placebo arm.

For individuals with Type 2 Diabetes, sotagliflozin was also studied for its impact on HbA1c. In NCT02926937, the change from baseline in HbA1c at Week 26 was -1.03 percentage of HbA1c for the sotagliflozin 400 mg arm, versus -0.34 percentage of HbA1c for placebo. Another study, NCT02926950, showed a change of -0.77 percentage of HbA1c for the sotagliflozin 400 mg + metformin arm, compared to -0.29 percentage of HbA1c for placebo + metformin. In NCT03066830, the sotagliflozin 400 mg arm reported a -0.70 percentage HbA1c change from baseline at Week 26, while the placebo arm reported 0.06 percentage HbA1c. For participants with Type 2 Diabetes and chronic kidney disease, NCT03242018 (SOTA-CKD4) found a change of -0.40 percentage of HbA1c for the sotagliflozin 400 mg arm versus -0.11 percentage of HbA1c for placebo. In NCT03242252 (SOTA-CKD3), the change from baseline in HbA1c at Week 26 was -0.32 percentage of HbA1c for the sotagliflozin 200 mg arm and -0.46 percentage of HbA1c for the sotagliflozin 400 mg arm, compared to -0.22 percentage of HbA1c for placebo.

All values presented here are sourced from primary registry reporting, and individual published papers should be consulted for clinical decisions.

All Sotagliflozin publications (109)

2026 (3 papers)

  1. Modeling Cardiorenal Protection with Sodium-Glucose Cotransporter 2 Inhibition in Type 1 Diabetes: An Analysis of DEPICT-1 and DEPICT-2.
    Nardone M, Kugathasan L, Sridhar VS, et al. · Clin J Am Soc Nephrol · 2026 · Derived
    PubMed: PMID 39918875 · NCT06217302 (SUGARNSALT) · Diabetes Mellitus, Type 1
  2. Residual Risk of Adverse Kidney and Cardiovascular Outcomes in Patients with CKD.
    Khan MS, Rashid AM, Shafi T, et al. · Clin J Am Soc Nephrol · 2026 · Background
    PubMed: PMID 39688924 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  3. Assessing Time in Range with Postprandial Glucose-Focused Titration of Ultra Rapid Lispro (URLi) in People with Type 1 Diabetes.
    Bergenstal RM, Bode BW, Bhargava A, et al. · Diabetes Ther · 2026 · Background
    PubMed: PMID 37740871 · NCT07325201 · Diabetes Mellitus, Type 1

2025 (7 papers)

  1. Rationale and Design of the SOTA-THROMBOSIS Trial (ATRU-VI): Antithrombotic Activities of Sotagliflozin Compared With Empagliflozin.
    Requena-Ibáñez JA, Zafar MU, Ferrandez-Escarabajal M, et al. · J Cardiovasc Pharmacol · 2025 · Derived
    PubMed: PMID 40748666 · NCT06618976 (SOTATHROMBUS) · Heart Failure
  2. Rationale and Design of the SOTA-P-CARDIA Trial (ATRU-V): Sotagliflozin in HFpEF Patients Without Diabetes.
    Pérez MS, Rodríguez-Capitán J, Requena-Ibáñez JA, et al. · Cardiovasc Drugs Ther · 2025 · Derived
    PubMed: PMID 37318685 · NCT05562063
  3. Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial.
    Aggarwal R, Bhatt DL, Szarek M, et al. · Lancet Diabetes Endocrinol · 2025 · Derived
    PubMed: PMID 39961315 · NCT03315143 (SCORED) · Diabetes Mellitus, Type 2
  4. Relationship Between Hypoglycemia Awareness Status on Clarke/Gold Methods and Counterregulatory Response to Hypoglycemia.
    Rubin NT, Seaquist ER, Eberly L, et al. · J Endocr Soc · 2025 · Background
    PubMed: PMID 35935070 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  5. Rapid and Simultaneous Initiation of Guideline-Directed Kidney Therapies in Patients with CKD and Type 2 Diabetes.
    Rashid AM, Khan MS, Cherney DZI, et al. · J Am Soc Nephrol · 2025 · Background
    PubMed: PMID 40327845 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  6. Simultaneous or Rapid Initiation of Combination Therapy for Heart Failure With Preserved Ejection Fraction.
    Greene SJ, Butler J, Fonarow GC, et al. · JAMA Cardiol · 2025 · Background
    PubMed: PMID 40042835 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  7. COmbinatioN effect of FInerenone anD EmpaglifloziN in participants with chronic kidney disease and type 2 diabetes using a UACR Endpoint (CONFIDENCE) trial: baseline clinical characteristics.
    Agarwal R, Green JB, Heerspink HJL, et al. · Nephrol Dial Transplant · 2025 · Background
    PubMed: PMID 39916475 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2

2024 (20 papers)

  1. Cost-Effectiveness of Sotagliflozin in SOLOIST-WHF.
    Weintraub WS, Kolm P, Dolman S, et al. · JACC Heart Fail · 2024 · Derived
    PubMed: PMID 38878007 · NCT03521934 · Diabetes Mellitus, Type 2
  2. Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial.
    Sridhar VS, Bhatt DL, Odutayo A, et al. · Clin J Am Soc Nephrol · 2024 · Derived
    PubMed: PMID 38277468 · NCT03315143 (SCORED) · Diabetes Mellitus, Type 2
  3. Experimental Designs for Multicomponent Interventions in Kidney and Cardiometabolic Diseases.
    Rossing P · J Am Soc Nephrol · 2024 · Derived
    PubMed: PMID 39078403 · NCT06082063 (Steno1) · Diabetes Mellitus, Type 1
  4. Sodium-glucose co-transporter protein 2 (SGLT2) inhibitors for people with chronic kidney disease and diabetes.
    Natale P, Tunnicliffe DJ, Toyama T, et al. · Cochrane Database Syst Rev · 2024 · Derived
    PubMed: PMID 38770818 · NCT03521934 · Diabetes Mellitus, Type 2
  5. Cost-effectiveness of sotagliflozin for the treatment of patients with diabetes and recent worsening heart failure.
    Kim J, Wang S, Sikirica S, et al. · J Comp Eff Res · 2024 · Derived
    PubMed: PMID 38771012 · NCT03521934 · Diabetes Mellitus, Type 2
  6. Effects of Sotagliflozin on Health Status in Patients With Worsening Heart Failure: Results From SOLOIST-WHF.
    Bhatt AS, Bhatt DL, Steg PG, et al. · J Am Coll Cardiol · 2024 · Derived
    PubMed: PMID 39260929 · NCT03521934 · Diabetes Mellitus, Type 2
  7. Finerenone in heart failure and chronic kidney disease with type 2 diabetes: FINE-HEART pooled analysis of cardiovascular, kidney and mortality outcomes.
    Vaduganathan M, Filippatos G, Claggett BL, et al. · Nat Med · 2024 · Background
    PubMed: PMID 39218030 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  8. Harnessing the Synergy of SGLT2 Inhibitors and Continuous Ketone Monitoring (CKM) in Managing Heart Failure among Patients with Type 1 Diabetes.
    Tecce N, de Alteriis G, de Alteriis G, et al. · Healthcare (Basel) · 2024 · Background
    PubMed: PMID 38610175 · NCT07325201 · Diabetes Mellitus, Type 1
  9. Expert Panel Recommendations for a Standardized Ambulatory Glucose Profile Report for Connected Insulin Pens.
    Simonson GD, Criego AB, Battelino T, et al. · Diabetes Technol Ther · 2024 · Background
    PubMed: PMID 38758213 · NCT07325201 · Diabetes Mellitus, Type 1
  10. Treatment Adherence in CKD and Support From Health care Providers: A Qualitative Study.
    Rivera E, Clark-Cutaia MN, Schrauben SJ, et al. · Kidney Med · 2024 · Background
    PubMed: PMID 36339664 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  11. Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
    Perkovic V, Tuttle KR, Rossing P, et al. · N Engl J Med · 2024 · Background
    PubMed: PMID 38785209 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  12. Estimated Lifetime Cardiovascular, Kidney, and Mortality Benefits of Combination Treatment With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Nonsteroidal MRA Compared With Conventional Care in Patients With Type 2 Diabetes and Albuminuria.
    Neuen BL, Heerspink HJL, Vart P, et al. · Circulation · 2024 · Background
    PubMed: PMID 37952217 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  13. KDOQI Commentary on the KDIGO 2022 Update to the Clinical Practice Guideline for Diabetes Management in CKD.
    Mottl AK, Nicholas SB · Am J Kidney Dis · 2024 · Background
    PubMed: PMID 38142396 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  14. Glucose metrics improvement in youths with type 1 diabetes using the Ambulatory Glucose Profile report: A real-world study.
    Maines E, Pertile R, Cauvin V, et al. · Diabetes Res Clin Pract · 2024 · Background
    PubMed: PMID 38797262 · NCT07325201 · Diabetes Mellitus, Type 1
  15. KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease.
    Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group · Kidney Int · 2024 · Background
    PubMed: PMID 38490803 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  16. Kidney and cardiovascular-protective benefits of combination drug therapies in chronic kidney disease associated with type 2 diabetes.
    Khan MS, Lea JP · BMC Nephrol · 2024 · Background
    PubMed: PMID 39090593 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  17. Update on Measuring Ketones.
    Huang J, Yeung AM, Bergenstal RM, et al. · J Diabetes Sci Technol · 2024 · Background
    PubMed: PMID 36794812 · NCT07325201 · Diabetes Mellitus, Type 1
  18. Major adverse kidney events as an endpoint in acute kidney injury trials: is it time for a RE-MAKE?
    Fuhrman DY, Bagshaw SM, Goldstein SL, et al. · Intensive Care Med · 2024 · Background
    PubMed: PMID 39145789 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  19. Impact of Rapid Up-Titration of Guideline-Directed Medical Therapies on Quality of Life: Insights From the STRONG-HF Trial.
    Čelutkienė J, Čerlinskaitė-Bajorė K, Cotter G, et al. · Circ Heart Fail · 2024 · Background
    PubMed: PMID 38445950 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  20. Roadmap to the Effective Use of Continuous Glucose Monitoring: Innovation, Investigation, and Implementation.
    Bergenstal RM · Diabetes Spectr · 2024 · Background
    PubMed: PMID 37982061 · NCT07325201 · Diabetes Mellitus, Type 1

2023 (10 papers)

  1. Metabolomic Profiling of the Effects of Dapagliflozin in Heart Failure With Reduced Ejection Fraction: DEFINE-HF.
    Selvaraj S, Fu Z, Jones P, et al. · Circulation · 2023 · Trial result
    PubMed: PMID 35603596 · NCT06510894 · Sarcoidosis
  2. Utility of serum ketone levels for assessment of myocardial glucose suppression for 18F-fluorodeoxyglucose PET in patients referred for evaluation of endocarditis.
    Madamanchi C, Weinberg RL, Murthy VL, et al. · J Nucl Cardiol · 2023 · Trial result
    PubMed: PMID 36823484 · NCT06510894 · Sarcoidosis
  3. The utility of beta-hydroxybutyrate in detecting myocardial glucose uptake suppression in patients undergoing inflammatory [18F]-FDG PET studies.
    Alfawara MS, Ahmed AI, Saad JM, et al. · Eur J Nucl Med Mol Imaging · 2023 · Trial result
    PubMed: PMID 36474124 · NCT06510894 · Sarcoidosis
  4. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and stage 3 chronic kidney disease.
    Cherney DZI, Ferrannini E, Umpierrez GE, et al. · Diabetes Obes Metab · 2023 · Derived
    PubMed: PMID 36782093 · NCT03242252 (SOTA-CKD3) · Diabetes Mellitus, Type 2
  5. Prevalence, Cost, and Burden of Diabetic Ketoacidosis.
    Virdi N, Poon Y, Abaniel R, et al. · Diabetes Technol Ther · 2023 · Background
    PubMed: PMID 37306442 · NCT07325201 · Diabetes Mellitus, Type 1
  6. Epidemiology of chronic kidney disease: an update 2022.
    Kovesdy CP · Kidney Int Suppl (2011) · 2023 · Background
    PubMed: PMID 35529086 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  7. Euglycemic diabetic ketoacidosis in the era of SGLT-2 inhibitors.
    Chow E, Clement S, Garg R, et al. · BMJ Open Diabetes Res Care · 2023 · Background
    PubMed: PMID 37797963 · NCT07325201 · Diabetes Mellitus, Type 1
  8. Management of the 'wicked' combination of heart failure and chronic kidney disease in the patient with diabetes.
    Bell DSH, McGill JB, Jerkins T, et al. · Diabetes Obes Metab · 2023 · Background
    PubMed: PMID 37409564 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  9. Differences in prevalence and management of chronic kidney disease among T2DM inpatients at the grassroots in Beijing and Taiyuan: a retrospective study.
    An L, Wang D, Shi X, et al. · J Health Popul Nutr · 2023 · Background
    PubMed: PMID 37408009 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  10. NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trial.
    Adamo M, Pagnesi M, Mebazaa A, et al. · Eur Heart J · 2023 · Background
    PubMed: PMID 37217188 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2

2022 (14 papers)

  1. Comparison of Exogenous Ketone Administration Versus Dietary Carbohydrate Restriction on Myocardial Glucose Suppression: A Crossover Clinical Trial.
    Selvaraj S, Margulies KB, Dugyala S, et al. · J Nucl Med · 2022 · Trial result
    PubMed: PMID 34675108 · NCT06510894 · Sarcoidosis
  2. The DAPA-DIET study: Metabolic response to Dapagliflozin combined with dietary carbohydrate restriction in patients with Type 2 Diabetes Mellitus and Obesity-A longitudinal cohort study.
    Hanson P, Randeva H, Cuthbertson DJ, et al. · Endocrinol Diabetes Metab · 2022 · Trial result
    PubMed: PMID 36266774 · NCT06510894 · Sarcoidosis
  3. Metabolic, Intestinal, and Cardiovascular Effects of Sotagliflozin Compared With Empagliflozin in Patients With Type 2 Diabetes: A Randomized, Double-Blind Study.
    Posch MG, Walther N, Ferrannini E, et al. · Diabetes Care · 2022 · Derived
    PubMed: PMID 35817022 · NCT03462069 · Diabetes Mellitus
  4. Prescribing SGLT2 Inhibitors in Patients With CKD: Expanding Indications and Practical Considerations.
    Yau K, Dharia A, Alrowiyti I, et al. · Kidney Int Rep · 2022 · Background
    PubMed: PMID 35812300 · NCT07325201 · Diabetes Mellitus, Type 1
  5. Effects of canagliflozin on serum potassium in people with diabetes and chronic kidney disease: the CREDENCE trial.
    Neuen BL, Oshima M, Perkovic V, et al. · Eur Heart J · 2022 · Background
    PubMed: PMID 34423370 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  6. Delay in seeking medical care for worsening heart failure symptoms: predictors and association with cardiac events.
    Lin CY, Hammash M, Miller JL, et al. · Eur J Cardiovasc Nurs · 2022 · Background
    PubMed: PMID 33580784 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  7. CKD Prevalence Among Patients With and Without Type 2 Diabetes: Regional Differences in the United States.
    Feng XS, Farej R, Dean BB, et al. · Kidney Med · 2022 · Background
    PubMed: PMID 35072048 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  8. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
    Davies MJ, Aroda VR, Collins BS, et al. · Diabetes Care · 2022 · Background
    PubMed: PMID 36148880 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  9. Amended STRONG-HF study design.
    Cotter G, Davison B, Metra M, et al. · Eur J Heart Fail · 2022 · Background
    PubMed: PMID 34529313 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  10. Improving the residual risk of renal and cardiovascular outcomes in diabetic kidney disease: A review of pathophysiology, mechanisms, and evidence from recent trials.
    Chaudhuri A, Ghanim H, Arora P, et al. · Diabetes Obes Metab · 2022 · Background
    PubMed: PMID 34779091 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  11. More Green, Less Red: How Color Standardization May Facilitate Effective Use of CGM Data.
    Bergenstal RM, Simonson GD, Heinemann L, et al. · J Diabetes Sci Technol · 2022 · Background
    PubMed: PMID 34711063 · NCT07325201 · Diabetes Mellitus, Type 1
  12. Randomized comparison of self-monitored blood glucose (BGM) versus continuous glucose monitoring (CGM) data to optimize glucose control in type 2 diabetes.
    Bergenstal RM, Mullen DM, Strock E, et al. · J Diabetes Complications · 2022 · Background
    PubMed: PMID 35131155 · NCT07325201 · Diabetes Mellitus, Type 1
  13. Renal Protection with SGLT2 Inhibitors: Effects in Acute and Chronic Kidney Disease.
    Bailey CJ, Day C, Bellary S, et al. · Curr Diab Rep · 2022 · Background
    PubMed: PMID 35113333 · NCT07325201 · Diabetes Mellitus, Type 1
  14. 'Time is prognosis' in heart failure: time-to-treatment initiation as a modifiable risk factor.
    Abdin A, Anker SD, Butler J, et al. · ESC Heart Fail · 2022 · Background
    PubMed: PMID 34655282 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2

2021 (12 papers)

  1. Implications of Altered Ketone Metabolism and Therapeutic Ketosis in Heart Failure.
    Selvaraj S, Kelly DP, Margulies KB, et al. · Circulation · 2021 · Trial result
    PubMed: PMID 32479196 · NCT06510894 · Sarcoidosis
  2. SGLT2 Inhibition Does Not Affect Myocardial Fatty Acid Oxidation or Uptake, but Reduces Myocardial Glucose Uptake and Blood Flow in Individuals With Type 2 Diabetes: A Randomized Double-Blind, Placebo-Controlled Crossover Trial.
    Lauritsen KM, Nielsen BRR, Tolbod LP, et al. · Diabetes · 2021 · Trial result
    PubMed: PMID 33334875 · NCT06510894 · Sarcoidosis
  3. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial.
    Szarek M, Bhatt DL, Steg PG, et al. · Ann Intern Med · 2021 · Derived
    PubMed: PMID 34152828 · NCT03521934 · Diabetes Mellitus, Type 2
  4. Diabetic Ketoacidosis and Related Events With Sotagliflozin Added to Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of the inTandem 1 and 2 Studies.
    Peters AL, McGuire DK, Danne T, et al. · Diabetes Care · 2021 · Derived
    PubMed: PMID 32928957 · NCT02421510 (inTandem2) · Diabetes Mellitus, Type 1
  5. Improvement in Patient-Reported Outcomes in Adults with Type 1 Diabetes Treated with Sotagliflozin plus Insulin Versus Insulin Alone.
    Danne T, Joish VN, Afonso M, et al. · Diabetes Technol Ther · 2021 · Derived
    PubMed: PMID 32721228 · NCT02421510 (inTandem2) · Diabetes Mellitus, Type 1
  6. Efficacy and safety of sotagliflozin in patients with type 2 diabetes and severe renal impairment.
    Cherney DZI, Ferrannini E, Umpierrez GE, et al. · Diabetes Obes Metab · 2021 · Derived
    PubMed: PMID 34338408 · NCT03242018 (SOTA-CKD4) · Diabetes Mellitus, Type 2
  7. Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study.
    Bode BW, Cengiz E, Wadwa RP, et al. · Diabetes Technol Ther · 2021 · Derived
    PubMed: PMID 32640846 · NCT02383940 · Diabetes Mellitus, Type 1
  8. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
    Bhatt DL, Szarek M, Steg PG, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 33200892 · NCT03521934 · Diabetes Mellitus, Type 2
  9. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
    Bhatt DL, Szarek M, Pitt B, et al. · N Engl J Med · 2021 · Derived
    PubMed: PMID 33200891 · NCT03315143 (SCORED) · Diabetes Mellitus, Type 2
  10. Continuous Ketone Monitoring: A New Paradigm for Physiologic Monitoring.
    Zhang JY, Shang T, Koliwad SK, et al. · J Diabetes Sci Technol · 2021 · Background
    PubMed: PMID 33834884 · NCT07325201 · Diabetes Mellitus, Type 1
  11. An Update on the Incidence and Burden of Diabetic Ketoacidosis in the U.S.
    Ramphul K, Joynauth J · Diabetes Care · 2021 · Background
    PubMed: PMID 33051332 · NCT07325201 · Diabetes Mellitus, Type 1
  12. The Gap to Fill: Rationale for Rapid Initiation and Optimal Titration of Comprehensive Disease-modifying Medical Therapy for Heart Failure with Reduced Ejection Fraction.
    Brownell NK, Ziaeian B, Fonarow GC, et al. · Card Fail Rev · 2021 · Background
    PubMed: PMID 34950508 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2

2020 (11 papers)

  1. Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics.
    Santos-Gallego CG, Requena-Ibanez JA, San Antonio R, et al. · J Am Coll Cardiol · 2020 · Trial result
    PubMed: PMID 30999996 · NCT06510894 · Sarcoidosis
  2. Insights Into Patients' Experience With Type 1 Diabetes: Exit Interviews From Phase III Studies of Sotagliflozin.
    Ervin C, Joish VN, Evans E, et al. · Clin Ther · 2020 · Derived
    PubMed: PMID 31587812 · NCT02421510 (inTandem2) · Diabetes Mellitus, Type 1
  3. Improved Time in Range and Glycemic Variability With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: A Pooled Analysis of 24-Week Continuous Glucose Monitoring Data From the inTandem Program.
    Danne T, Cariou B, Buse JB, et al. · Diabetes Care · 2020 · Derived
    PubMed: PMID 30833371 · NCT02384941 (inTandem1) · Diabetes Mellitus, Type 1
  4. Dose-dependent glycometabolic effects of sotagliflozin on type 1 diabetes over 12 weeks: The inTandem4 trial.
    Baker C, Wason S, Banks P, et al. · Diabetes Obes Metab · 2020 · Derived
    PubMed: PMID 31264767 · NCT02459899 (inTandem4) · Diabetes Mellitus, Type 1
  5. The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes.
    van Raalte DH, Bjornstad P, Persson F, et al. · Diabetes Care · 2020 · Background
    PubMed: PMID 31371432 · NCT06217302 (SUGARNSALT) · Diabetes Mellitus, Type 1
  6. Acute kidney injury and adverse renal events in patients receiving SGLT2-inhibitors: A systematic review and meta-analysis.
    Menne J, Dumann E, Haller H, et al. · PLoS Med · 2020 · Background
    PubMed: PMID 31815931 · NCT07325201 · Diabetes Mellitus, Type 1
  7. Analysis from the EMPA-REG OUTCOME® trial indicates empagliflozin may assist in preventing the progression of chronic kidney disease in patients with type 2 diabetes irrespective of medications that alter intrarenal hemodynamics.
    Mayer GJ, Wanner C, Weir MR, et al. · Kidney Int · 2020 · Background
    PubMed: PMID 31142441 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  8. Dapagliflozin in Patients with Chronic Kidney Disease.
    Heerspink HJL, Stefánsson BV, Correa-Rotter R, et al. · N Engl J Med · 2020 · Background
    PubMed: PMID 32970396 · NCT07325201 · Diabetes Mellitus, Type 1
  9. Sodium-glucose co-transporter inhibitors, their role in type 1 diabetes treatment and a risk mitigation strategy for preventing diabetic ketoacidosis: The STOP DKA Protocol.
    Goldenberg RM, Gilbert JD, Hramiak IM, et al. · Diabetes Obes Metab · 2020 · Background
    PubMed: PMID 31183975 · NCT07325201 · Diabetes Mellitus, Type 1
  10. The Relationships Between Time in Range, Hyperglycemia Metrics, and HbA1c.
    Beck RW, Bergenstal RM, Cheng P, et al. · J Diabetes Sci Technol · 2020 · Background
    PubMed: PMID 30636519 · NCT07325201 · Diabetes Mellitus, Type 1
  11. Burden and Outcomes of Heart Failure Hospitalizations in Adults With Chronic Kidney Disease.
    Bansal N, Zelnick L, Bhat Z, et al. · J Am Coll Cardiol · 2020 · Background
    PubMed: PMID 31146814 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2

2019 (6 papers)

  1. Sotagliflozin, the first dual SGLT inhibitor: current outlook and perspectives.
    Cefalo CMA, Cinti F, Moffa S, et al. · Cardiovasc Diabetol · 2019 · Derived
    PubMed: PMID 30819210 · NCT03315143 (SCORED) · Diabetes Mellitus, Type 2
  2. SGLT Inhibitors for Type 1 Diabetes: Proceed With Extreme Caution.
    Wolfsdorf JI, Ratner RE · Diabetes Care · 2019 · Background
    PubMed: PMID 31110116 · NCT07325201 · Diabetes Mellitus, Type 1
  3. Time Savings Using a Standardized Glucose Reporting System and Ambulatory Glucose Profile.
    Mullen DM, Bergenstal R, Criego A, et al. · J Diabetes Sci Technol · 2019 · Background
    PubMed: PMID 29169243 · NCT07325201 · Diabetes Mellitus, Type 1
  4. Sotagliflozin: First Global Approval.
    Markham A, Keam SJ · Drugs · 2019 · Background
    PubMed: PMID 31172412 · NCT06217302 (SUGARNSALT) · Diabetes Mellitus, Type 1
  5. International Consensus on Risk Management of Diabetic Ketoacidosis in Patients With Type 1 Diabetes Treated With Sodium-Glucose Cotransporter (SGLT) Inhibitors.
    Danne T, Garg S, Peters AL, et al. · Diabetes Care · 2019 · Background
    PubMed: PMID 30728224 · NCT07325201 · Diabetes Mellitus, Type 1
  6. Reduction of Cardiovascular Risk and Improved Estimated Glomerular Filtration Rate by SGLT2 Inhibitors, Including Dapagliflozin, Is Consistent Across the Class: An Analysis of the Placebo Arm of EXSCEL.
    Clegg LE, Heerspink HJL, Penland RC, et al. · Diabetes Care · 2019 · Background
    PubMed: PMID 30523029 · NCT07325201 · Diabetes Mellitus, Type 1

2018 (6 papers)

  1. HbA1c and Hypoglycemia Reductions at 24 and 52 Weeks With Sotagliflozin in Combination With Insulin in Adults With Type 1 Diabetes: The European inTandem2 Study.
    Danne T, Cariou B, Banks P, et al. · Diabetes Care · 2018 · Derived
    PubMed: PMID 29937431 · NCT02421510 (inTandem2) · Diabetes Mellitus, Type 1
  2. Sotagliflozin in Combination With Optimized Insulin Therapy in Adults With Type 1 Diabetes: The North American inTandem1 Study.
    Buse JB, Garg SK, Rosenstock J, et al. · Diabetes Care · 2018 · Derived
    PubMed: PMID 29937430 · NCT02384941 (inTandem1) · Diabetes Mellitus, Type 1
  3. The mortality risk of deferring optimal medical therapy in heart failure: a systematic comparison against norms for surgical consent and patient information leaflets.
    Zaman S, Zaman SS, Scholtes T, et al. · Eur J Heart Fail · 2018 · Background
    PubMed: PMID 28597606 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  4. Strategy for Mitigating DKA Risk in Patients with Type 1 Diabetes on Adjunctive Treatment with SGLT Inhibitors: A STICH Protocol.
    Garg SK, Peters AL, Buse JB, et al. · Diabetes Technol Ther · 2018 · Background
    PubMed: PMID 30129772 · NCT07325201 · Diabetes Mellitus, Type 1
  5. Effect of Continuous Glucose Monitoring on Glycemic Control, Acute Admissions, and Quality of Life: A Real-World Study.
    Charleer S, Mathieu C, Nobels F, et al. · J Clin Endocrinol Metab · 2018 · Background
    PubMed: PMID 29342264 · NCT07325201 · Diabetes Mellitus, Type 1
  6. Continuous glucose monitoring: transforming diabetes management step by step.
    Bergenstal RM · Lancet · 2018 · Background
    PubMed: PMID 29459022 · NCT07325201 · Diabetes Mellitus, Type 1

2017 (4 papers)

  1. Effects of Sotagliflozin Added to Insulin in Patients with Type 1 Diabetes.
    Garg SK, Henry RR, Banks P, et al. · N Engl J Med · 2017 · Derived
    PubMed: PMID 28899222 · NCT02531035 (inTandem3) · Diabetes Mellitus, Type 1
  2. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
    Neal B, Perkovic V, Matthews DR, et al. · N Engl J Med · 2017 · Background
    PubMed: PMID 29166232 · NCT07325201 · Diabetes Mellitus, Type 1
  3. Development and Validation of a Tool to Identify Patients With Type 2 Diabetes at High Risk of Hypoglycemia-Related Emergency Department or Hospital Use.
    Karter AJ, Warton EM, Lipska KJ, et al. · JAMA Intern Med · 2017 · Background
    PubMed: PMID 28828479 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2
  4. Defining end-stage renal disease in clinical trials: a framework for adjudication.
    Agarwal R · Nephrol Dial Transplant · 2017 · Background
    PubMed: PMID 26264780 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2

2016 (1 paper)

  1. Sodium Glucose Cotransporter 2 Inhibitors in the Treatment of Diabetes Mellitus: Cardiovascular and Kidney Effects, Potential Mechanisms, and Clinical Applications.
    Heerspink HJ, Perkins BA, Fitchett DH, et al. · Circulation · 2016 · Background
    PubMed: PMID 27470878 · NCT07325201 · Diabetes Mellitus, Type 1

2015 (1 paper)

  1. Sotagliflozin, a Dual SGLT1 and SGLT2 Inhibitor, as Adjunct Therapy to Insulin in Type 1 Diabetes.
    Sands AT, Zambrowicz BP, Rosenstock J, et al. · Diabetes Care · 2015 · Derived
    PubMed: PMID 26049551 · NCT01742208 · Diabetes Mellitus, Type 1

2013 (2 papers)

  1. Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosis.
    Kron J, Sauer W, Schuller J, et al. · Europace · 2013 · Trial result
    PubMed: PMID 23002195 · NCT06510894 · Sarcoidosis
  2. Recommendations for standardizing glucose reporting and analysis to optimize clinical decision making in diabetes: the ambulatory glucose profile.
    Bergenstal RM, Ahmann AJ, Bailey T, et al. · J Diabetes Sci Technol · 2013 · Background
    PubMed: PMID 23567014 · NCT07325201 · Diabetes Mellitus, Type 1

2012 (3 papers)

  1. Variable cardiac 18FDG patterns seen in oncologic positron emission tomography computed tomography: importance for differentiating normal physiology from cardiac and paracardiac disease.
    Maurer AH, Burshteyn M, Adler LP, et al. · J Thorac Imaging · 2012 · Trial result
    PubMed: PMID 21629130 · NCT06510894 · Sarcoidosis
  2. Utility of high fat and low carbohydrate diet in suppressing myocardial FDG uptake.
    Harisankar CN, Mittal BR, Agrawal KL, et al. · J Nucl Cardiol · 2012 · Trial result
    PubMed: PMID 21732228 · NCT06510894 · Sarcoidosis
  3. The size of a pilot study for a clinical trial should be calculated in relation to considerations of precision and efficiency.
    Sim J, Lewis M · J Clin Epidemiol · 2012 · Background
    PubMed: PMID 22169081 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2

2011 (1 paper)

  1. Chronic kidney disease and the risk of end-stage renal disease versus death.
    Dalrymple LS, Katz R, Kestenbaum B, et al. · J Gen Intern Med · 2011 · Background
    PubMed: PMID 20853156 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2

2010 (1 paper)

  1. Impact of carbohydrate restriction with and without fatty acid loading on myocardial 18F-FDG uptake during PET: A randomized controlled trial.
    Cheng VY, Slomka PJ, Ahlen M, et al. · J Nucl Cardiol · 2010 · Trial result
    PubMed: PMID 20013165 · NCT06510894 · Sarcoidosis

2008 (1 paper)

  1. Better outcomes for patients treated at hospitals that participate in clinical trials.
    Majumdar SR, Roe MT, Peterson ED, et al. · Arch Intern Med · 2008 · Background
    PubMed: PMID 18362259 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2

2006 (1 paper)

  1. National survey on status of steroid therapy for cardiac sarcoidosis in Japan.
    Hiramitsu S, Morimoto S, Uemura A, et al. · Sarcoidosis Vasc Diffuse Lung Dis · 2006 · Trial result
    PubMed: PMID 16315784 · NCT06510894 · Sarcoidosis

2004 (2 papers)

  1. A study of sarcoidosis; based on a combined investigation of 160 cases including 30 autopsies from The Johns Hopkins Hospital and Massachusetts General Hospital.
    LONGCOPE WT, FREIMAN DG · Medicine (Baltimore) · 2004 · Trial result
    PubMed: PMID 14899212 · NCT06510894 · Sarcoidosis
  2. Chronic kidney disease and cardiovascular disease in the Medicare population.
    Collins AJ, Li S, Gilbertson DT, et al. · Kidney Int Suppl · 2004 · Background
    PubMed: PMID 14531770 · NCT07547878 (RAPID-CKD) · Diabetes Mellitus, Type 2

2003 (1 paper)

  1. Metabolism of the human heart. II. Studies on fat, ketone and amino acid metabolism.
    BING RJ, SIEGEL A, UNGAR I, et al. · Am J Med · 2003 · Trial result
    PubMed: PMID 13148192 · NCT06510894 · Sarcoidosis

1993 (1 paper)

  1. Myocardial sarcoidosis.
    Sharma OP, Maheshwari A, Thaker K, et al. · Chest · 1993 · Trial result
    PubMed: PMID 8417889 · NCT06510894 · Sarcoidosis

1979 (1 paper)

  1. Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis.
    Silverman KJ, Hutchins GM, Bulkley BH, et al. · Circulation · 1979 · Trial result
    PubMed: PMID 709777 · NCT06510894 · Sarcoidosis

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).